NCT01988662 - UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Neovacular Age-related Macular Degeneration

Interventions

PROCEDURE

Neovascular Age-related Macular Degeneration

Blood measurement

Trial Locations (24)

1102

Novartis Investigative Site, Quezon City

1209

Novartis Investigative Site, Makati City

1605

Novartis Investigative Site, Pasig

10002

Novartis Investigative Site, Taipei

10330

Novartis Investigative Site, Bangkok

10400

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

33305

Novartis Investigative Site, Linkou District

46200

Novartis Investigative Site, Petaling Jaya

49100

Novartis Investigative Site, Petah Tikva

59200

Novartis Investigative Site, Kuala Lumpur

84101

Novartis Investigative Site, Beersheba

117549

Novartis Investigative Site, Singapore

574623

Novartis Investigative Site, Singapore

3436212

Novartis Investigative Site, Haifa

3525408

Novartis Investigative Site, Haifa

4428164

Novartis Investigative Site, Kfar Saba

6423906

Novartis Investigative Site, Tel Aviv

7610001

Novartis Investigative Site, Rehovot

03722

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

705-703

Novartis Investigative Site, Daegu

06273

Novartis Investigative Site, Seoul

150-950

Novartis Investigative Site, Seoul